Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas

Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas

Brentuximab vedotin (BV) has demonstrated efficacy against CD30+ peripheral T-cell lymphoma (PTCL). We herein report a case of CD30+ peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) that emerged one month after completing BV, cyclophosphamide, doxorubicin, and prednisone (BV-CHP) thera...

Full description

Saved in:
Bibliographic Details
Main Authors: Gen Hasegawa, Noriharu Nakagawa, Yoshimichi Ueda, Masahide Yamazaki
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Leukemia Research Reports
Subjects:
Peripheral T-cell lymphoma
Brentuximab vedotin
Retreatment
Different phenotype
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048925000020
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items